CoChat

siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy

Open access
Wang, Pingjie, Gong, Jing, Xu, Yilin, Xia, Xinhua · 2026 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.

Abstract

siRNA, as a precise, specific, and highly effective gene-silencing therapy, has been extensively studied. Before reaching tumor cell targets, siRNA formulations must overcome multiple extracellular barriers, including clearance from the bloodstream, membrane impermeability, capture by the mononuclear phagocyte system (MPS), rapid renal excretion, endosomal escape, and precise recognition of target cells. These challenges limit siRNA’s clinical application. Consequently, various modifications have been applied to siRNA to enhance transfection efficiency, while researchers continue to pursue improved siRNA-targeting delivery systems. Nanotechnology offers a rational technical approach to address siRNA delivery. Nanoparticles can increase transfection efficiency while exhibiting lower cytotoxicity and reduced off-target effects. Various matrices have been employed to construct nanoparticles for targeted therapeutic delivery. This review briefly discusses siRNA nanoparticle delivery strategies, illustrates examples of various siRNA nanodelivery systems, such as lipid nanoparticles, polymeric siRNA nanoparticles, inorganic nanoparticles, hybrid nanoparticles, and conjugate-siRNA delivery systems, and introduces clinical trials of siRNA-loaded nanoparticles for cancer treatment, which can provide valuable references for further research and clinical application of siRNA nanoparticle delivery systems.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms27073032

Cites

157 of 157 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 RNA Interference Process. A–B. dsRNA is cleaved by Dicer into siRNA, which is then unwound. The guide strand is assembled into the RNA-induced silencing complex (RISC), containing Argonaute proteins (catalytic components) for cleavage. B–C. The antisense strand pairs perfectly with the target mRNA as the guide strand. C–D. mRNA is cleaved and degraded.
Figure 1 RNA Interference Process. A–B. dsRNA is cleaved by Dicer into siRNA, which is then unwound. The guide strand is assembled into the RNA-induced silencing complex (RISC), containing Argonaute proteins (catalytic components) for cleavage. B–C. The antisense strand pairs perfectly with the target mRNA as the guide strand. C–D. mRNA is cleaved and degraded.CC BY · PubMed Central
Figure 2 The delivery difficulties in siRNA formulations before reaching the tumor cell membrane. After siRNA is loaded onto nanoparticles and administered intravenously into the bloodstream, it encounters multiple barriers, including blood clearance, RES cell phagocytosis, nuclease degradation, physicochemical modifications, renal filtration, and other barriers. It then traverses the vascular wall via the EPR effect, relying on vascular permeability, and subsequently diffuses within the tumor stroma. Confronted by high interstitial pressure, cellular crowding, and dense ECM, it ultimately reaches target cells through the specificity of targeting ligands.
Figure 2 The delivery difficulties in siRNA formulations before reaching the tumor cell membrane. After siRNA is loaded onto nanoparticles and administered intravenously into the bloodstream, it encounters multiple barriers, including blood clearance, RES cell phagocytosis, nuclease degradation, physicochemical modifications, renal filtration, and other barriers. It then traverses the vascular wall via the EPR effect, relying on vascular permeability, and subsequently diffuses within the tumor stroma. Confronted by high interstitial pressure, cellular crowding, and dense ECM, it ultimately reaches target cells through the specificity of targeting ligands.CC BY · PubMed Central
Figure 3 Schematic diagram of partial chemical modification structures of siRNA.
Figure 3 Schematic diagram of partial chemical modification structures of siRNA.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 157 references

Cited by

See all 4

Metadata

Authors
Wang, P., Gong, J., Xu, Y., & Xia, X.
Affiliations
Hunan University of Traditional Chinese Medicine (CN)
Corresponding author
Xia, Xinhua
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2026-03-26
Volume
27
Issue
7
Pages
3032
ISSN
1422-0067 (ISSN-L)
OpenAlex
W7140659748
Cited by
4
References
150
Citations by year
2026: 4
FWCI
2.68
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Science Foundation of China https://ror.org/01h0zpd94 (81573621)
  • Hunan Provincial Natural Science Foundation—Departmental Joint Fund (2025JJ80199)
  • Key Research and Development Plan of Hunan Province (2017SK2122)
  • Key Discipline Project on Chinese Pharmacology of Hunan University of Chinese Medicine (202302)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
Keywords
siRNA, nanoparticle delivery, lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, hybrid nanostructures, endosomal escape, transfection efficiency, siRNA modification, cancer gene therapy, clinical trials
MeSH terms
Nanoparticle Drug Delivery System, Animals, Clinical Trials as Topic, Humans, Neoplasms, Genetic Therapy, Drug Delivery Systems, Gene Transfer Techniques, RNA Interference, RNA, Small Interfering, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy. https://app.cochat.ai/papers/10.3390/ijms27073032
The paper
Wang, P., Gong, J., Xu, Y., & Xia, X. (2026). siRNA Nanoparticle Delivery Strategies and Clinical Trial Advances in Tumor Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27073032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.